Results 91 to 100 of about 5,389 (186)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

ESMO Open, 2019
The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BRAFi+MEKi) represents an established therapeutic option in patients with BRAF-mutated, advanced melanoma.
Jan Leipe, Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, Jessica C Hassel, Daniela Heller-Schenck, Matthias Pauschinger, Arndt Vogel, Lisa Zimmer, Ralf Gutzmer   +9 more
doaj   +1 more source

Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report

Case Reports in Dermatology
Introduction: The development of new and changing melanocytic lesions has been increasingly reported as an adverse dermatologic toxicity of BRAF inhibitor therapy.
Karen Lam, Gregory A. Gates, Daniel Q. Bach, Kyle Cheng   +3 more
doaj   +1 more source

The road to therapy for myeloid sarcoma: navigating the complexities of subclonal MAPK/ERK mutations and clonal evolution

The Journal of Pathology: Clinical Research, Volume 11, Issue 6, November 2025.
DuJiang Yang, Jiexiang Yang, GuoYou Wang
wiley   +1 more source

Precision Oncology in Duodenal Adenocarcinoma: A Case of Metastatic BRAF V600E-mutant Disease Treated with Encorafenib, Cetuximab, Chemotherapy, and Immunotherapy

Journal of Cancer Research and Practice
Duodenal adenocarcinoma is a rare malignancy that is often managed with protocols extrapolated from colorectal cancer (CRC) due to limited disease-specific evidence.
Yi-Chieh Chen, Yee Chao, Jan-Mou Lee, Cheng-Yu Tang   +3 more
doaj   +1 more source

A Model Based Approach for Translation in Oncology - From Xenografts to RECIST [PDF]

, 2022
A major problem in drug development is translating results from preclinical studies to the clinical setting. Therefore, we evalu ate the translational potential of semi mechanistic tumor models (based on xenograft data) to predict clinical oncology ...
Baaz, Marcus, Cardilin, Tim, Jirstrand, Mats, Lignet, Floriane   +3 more
core  

BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer

ESMO Gastrointestinal Oncology
Background: While the triplet combination of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CET) yielded a higher response rate compared with the doublet combination of ENCO plus CET, no significant survival benefits of the triplet combination ...
Y. Matsubara, H. Bando, D. Kotani, Y. Kagawa, K. Harada, H. Osumi, N. Izawa, T. Kawakami, S. Boku, T. Matsumoto, M. Wakabayashi, T. Yoshino   +11 more
doaj   +1 more source

[Comment] Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer

结直肠肛门外科
[Background] The open-label, phase 3 BREAKWATER study evaluated first-line encorafenib plus cetuximab with or without chemotherapy (oxaliplatin, leucovorin, and 5-FU) (EC±mFOLFOX6) vs.
Xie Dan, Bi Liang
doaj   +1 more source

Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways [PDF]

We thank Isabel Crespo and Sara Ozcoz from the Cytomics Core Facility of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) for technical assistance.
Bertran-Alamillo, Jordi, Codony-Servat, Jordi, d'Hondt, E., García-Peláez, B., García-Roman, Sílvia, Garzón-Ibáñez, M., Giménez-Capitán, A., Jordana-Ariza, Núria, Molina-Vila, Miguel Ángel, Rosell, Rafael, Vives-Usano, M.   +10 more
core   +1 more source

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC [PDF]

Immunotherapy; Metastatic colorectal cancer; Targeted therapyImmunoteràpia; Càncer colorectal metastàtic; Teràpia dirigidaInmunoterapia; Cáncer colorrectal metastásico; Terapia dirigidaPatients with both BRAF V600E mutations and microsatellite ...
Bekaii-Saab, Tanios, Elez, Elena, Kopetz, Scott, Tabernero, Josep, taieb, julien, Yoshino, Takayuki   +5 more
core   +1 more source

Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer [PDF]

, 2021
Akhoundova, Dilara, Britschgi, Christian, Fritsch, Ralph M, Hussung, Saskia, Kiessling, Michael, Pietge, Heike, Rechsteiner, Markus, Weber, Achim, Zoche, Martin   +8 more
core   +1 more source